Sudeep Pharma Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2026 • Pharmaceutical, Food & Nutrition: 56.5% • Speciality Ingredients: 43.5%
AI Sector View
AI GENERATEDChemicals
The available domestic chemical proxies are mixed to weak. Fertilizers output was -8.0% YoY (2026-07) and sale quantity of fertilisers was 0.0% YoY (2026-05), although that high-frequency barometer is stale. FPI positioning is less negative than before, with net 3-month outflow only INR -11 crore versus INR -1229 crore in the prior 3 months to 2026-08-31, but the weak sector driver argues for a neutral stance.
PROS
- Company has delivered good profit growth of 39.2% CAGR over last 5 years
- Company has a healthy return on capital (ROCE) of 37.7%
- Company has a good return on equity (ROE) track record: 3 Years ROE 34.7%
- Company has consistently been profitable over the last 5 years
- Company has delivered good sales growth of 24.5% CAGR over last 5 years
- Operating margins have improved to 34.1% from 23.3%
CONS
- Promoter holding has decreased over last 2 years: -23.8pp
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.41x)
- Equity base is being diluted - shares outstanding up 701.6%
- Working capital days have increased from 174 to 235 days
- Stock is trading at 7.6x its book value
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1868.50 | 37.06 | 448315.74 | 0.86 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9482.75 | 86.06 | 251737.22 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4931.90 | 86.01 | 187593.62 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1129.00 | 24.95 | 112618.18 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1368.00 | 32.79 | 110515.04 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1933.25 | 95.54 | 104455.86 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| AUROPHARMA | 1690.00 | 26.19 | 97238.86 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2092.00 | 17.30 | 95660.02 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1143.20 | 29.61 | 95420.61 | 0.70 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2266.00 | 45.82 | 93596.02 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2439.55 | 38.29 | 68850.12 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| SUDEEPPHRM | 1276.00 | 78.91 | 14412.24 | 0.12 | 405.87 | 1197.99 | 1582.70 | 1166.99 | 28.50 | 34.70 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| 149 | 116 | 158 | 125 | 163 | 172 | 182 | 158 | |
| 85 | 76 | 99 | 86 | 107 | 112 | 120 | 109 | |
| Operating Profit | 63 | 39 | 59 | 39 | 55 | 60 | 63 | 49 |
| OPM % | 42.65% | 34.01% | 37.31% | 31.15% | 34.10% | 34.80% | 34.33% | 30.86% |
| 2 | 2 | 4 | 5 | 10 | 7 | 6 | 5 | |
| Interest | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Profit before Tax | 62 | 38 | 58 | 44 | 60 | 62 | 63 | 54 |
| Tax % | 21.01% | 23.77% | 23.63% | 29.05% | 21.43% | 22.79% | 22.59% | 25.24% |
| Net Profit | 0 | 0 | 0 | 31 | 47 | 48 | 49 | 41 |
| 4.49 | 2.65 | 4.07 | 2.84 | 4.20 | 4.29 | 4.38 | 3.59 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 123 | 215 | 343 | 429 | 459 | 502 | 642 | 676 | |
| 98 | 171 | 276 | 339 | 277 | 311 | 419 | 449 | |
| Operating Profit | 25 | 44 | 67 | 90 | 182 | 191 | 223 | 227 |
| OPM % | 20.64% | 20.49% | 19.67% | 21.03% | 39.73% | 38.05% | 34.69% | 33.58% |
| 3 | 3 | 7 | 10 | 6 | 9 | 29 | 29 | |
| Interest | 1 | 1 | 2 | 6 | 5 | 7 | 9 | 8 |
| Depreciation | 3 | 4 | 5 | 8 | 9 | 11 | 15 | 16 |
| Profit before Tax | 25 | 43 | 69 | 86 | 175 | 183 | 228 | 238 |
| Tax % | 26.68% | 22.50% | 26.87% | 27.52% | 23.81% | 24.13% | 23.58% | 22.96% |
| Net Profit | 18 | 33 | 50 | 62 | 133 | 139 | 174 | 184 |
| EPS | 128.02 | 236.61 | 356.01 | 5.74 | 945.26 | 14.27 | 15.31 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 9.80% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- 24%
- 3 Years:
- 14%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- 39%
- 3 Years:
- 41%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- —
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 34%
- 3 Years:
- 35%
- Last Year:
- 25%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 1 | 1 | 1 | 1 | 1 | 10 | 11 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 15 |
| 80 | 113 | 162 | 222 | 355 | 481 | 872 | |
| 20 | 31 | 84 | 83 | 68 | 127 | 167 | |
| Trade Payables | 9 | 18 | 27 | 38 | 51 | 60 | 68 |
| 21 | 50 | 70 | 75 | 39 | 39 | 40 | |
| Total Liabilities | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 |
| 60 | 68 | 137 | 158 | 180 | 189 | 337 | |
| Capital Work in Progress | 8 | 24 | 8 | 26 | 45 | 88 | 178 |
| 6 | 19 | 0 | 3 | 0 | 0 | 0 | |
| 9 | 17 | 37 | 71 | 67 | 129 | 216 | |
| 0 | 0 | 0 | 0 | 145 | 185 | 228 | |
| Cash & Bank | 4 | 12 | 21 | 10 | 14 | 52 | 115 |
| 44 | 73 | 141 | 151 | 63 | 73 | 101 | |
| Total Assets | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 16 | 46 | 15 | 71 | 66 | 49 | 70 | |
| Cash from Investing | -22 | -40 | -38 | -50 | -49 | -79 | -331 |
| Cash from Financing | 12 | 13 | 51 | -10 | -13 | 53 | 247 |
| -0 | 8 | 10 | -11 | 4 | 23 | -14 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-08-11 - Sudeep Pharma Limited has informed the Exchange about Transcript
2026-08-06 - Sudeep Pharma Limited has informed the Exchange regarding 'General Update'.
2026-08-05 - Sudeep Pharma Limited has informed the Exchange about Link of Recording
2026-08-05 - Sudeep Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 04, 2026. Further, the company has informed the Exchange regarding voting results.
2026-08-05 - Sudeep Pharma Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-04 - Sudeep Pharma Limited has informed the Exchange about Investor Presentation
2026-08-04 - Sudeep Pharma Limited has informed the Exchange about Investor Presentation
2026-08-04 - Sudeep Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-04 - Sudeep Pharma Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 04, 2026
News
Recent coverage and analyst commentary for SUDEEPPHRM
Loading news…
AI Stock Analyst
Sudeep Pharma Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account